- cafead Aug 18, 2022 at 12:52: PM
via After penning a deal with Orion back in May, Jemincare is back at the licensing deal table, inking a development and sales deal with Roche’s Genentech unit that is on the lookout for a new prostate cancer drug after the recent flop of its phase 3 asset ipatasertib.
article source
article source